NCT07463781Not yet recruiting
Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy
Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy: a Multicenter Observational Prospective Study
Source: ClinicalTrials.gov · Last updated 13 Mar 2026
Brief summary (registry, in English)
This is an observational, multicenter, prospective cohort study including patients treated with CAR-T in Italian centers. Patients eligible for enrollment in the study will be consecutively included in Italian FIL centers. A longitudinal survey will be carried out by collecting patients' data before starting CAR-T (T0) and after 6 (T1), 12 (T2) and 24 (T3) months after CAR-T infusion.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 24 Feb 2026
- Start date
- May 2026
- Primary completion date
- May 2029
- Lead sponsor
- Fondazione Italiana Linfomi - ETS
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT07463781
What you commit to
- Study type: Observational
- Planned participants: 100
- From May 2026 to the primary completion date, May 2029
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients that received brain/neuroaxis radiotherapy.
Other illness
- Patients with CNS disease localization.
- Pre-existing severe psychiatric or neurologic comorbidities influencing neurocognitive assessment.
Other
- Patient with histological diagnosis of mantle cell lymphoma (MCL) or acute lymphoblastic leukemia (ALL)
Who the study is looking for
- Patients with previous diagnosis of Diffuse Large B Cell Lymphoma or High- Grade B Cell Lymphoma (DLBCL/HGBL), arising de novo or transformed from a previous indolent histotype (transformed Follicular Lymphoma or transformed Marginal Zone Lymphoma), Primary Mediastinal B Cell Lymphoma (PMBCL).
- Patients undergoing CD19-targeted CAR-T cell salvage therapy for relapsed/refractory disease according to AIFA inclusion criteria.
- Age over 18-years-old at the time of lymphoma diagnosis.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| SCDU Ematologia - AOU SS. Antonio e Biagio e Cesare Arrigo di Alessandria Coordinator of this site? Confirm its status | Alessandria | Italy | Unknown status |
| Clinica di Ematologia, AOU Ospedali Riuniti Coordinator of this site? Confirm its status | Ancona | Italy | Unknown status |
| USD-TMO Adulti - ASST Spedali Civili di Brescia Coordinator of this site? Confirm its status | Brescia | Italy | Unknown status |
| Divisione di Ematologia - A.O. Ospedali Riuniti Villa Sofia-Cervello Coordinator of this site? Confirm its status | Palermo | Italy | Unknown status |
| Ematologia - Grande Ospedale Metropolitano Bianchi Melacrino Morelli Coordinator of this site? Confirm its status | Reggio Calabria | Italy | Unknown status |
| Ematologia - Università Cattolica S. Cuore Coordinator of this site? Confirm its status | Roma | Italy | Unknown status |
| SC Ematologia - Ospedale "S.G. Moscati" Coordinator of this site? Confirm its status | Taranto | Italy | Unknown status |
| SOC Clinica Ematologica - Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) Coordinator of this site? Confirm its status | Udine | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.